Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Share-based Compensation (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Share-based Compensation for 4 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 4.71% to $7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.0 million through Dec 2025, down 7.7% year-over-year, with the annual reading at $31.0 million for FY2025, 7.7% down from the prior year.
  • Share-based Compensation for Q4 2025 was $7.9 million at Centessa Pharmaceuticals, up from $7.2 million in the prior quarter.
  • The five-year high for Share-based Compensation was $8.6 million in Q2 2024, with the low at $5.6 million in Q2 2022.
  • Average Share-based Compensation over 4 years is $7.4 million, with a median of $7.5 million recorded in 2023.
  • The sharpest move saw Share-based Compensation rose 28.73% in 2023, then fell 14.89% in 2025.
  • Over 4 years, Share-based Compensation stood at $6.6 million in 2022, then increased by 12.29% to $7.4 million in 2023, then rose by 12.09% to $8.3 million in 2024, then dropped by 4.71% to $7.9 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $7.9 million, $7.2 million, and $7.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.